Gu Namyi, Park Sang-In, Chung Hyewon, Jin Xuanyou, Lee SeungHwan, Kim Tae-Eun
Department of Clinical Pharmacology and Therapeutics, Clinical Trial Center, Dongguk University College of Medicine and Ilsan Hospital, Goyang, Korea.
Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon, Korea.
Transl Clin Pharmacol. 2020 Mar;28(1):17-33. doi: 10.12793/tcp.2020.28.e4. Epub 2020 Mar 31.
Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic control. The combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a sodium-glucose cotransporter type 2 (SGLT2) inhibitor is a promising option of the combination therapies in terms of safety as well as efficacy. Despite of the value of combination therapy of these two agents, the pharmacokinetic drug interactions between these two classes of agents have been evaluated in a few drugs. Thus, we reviewed the potential pharmacokinetic drug interaction based on the metabolism- and transporter-mediated drug interaction information as well as drug interaction studies in human, between a DPP-4 inhibitor and a SGLT2 inhibitor which are marketed in South Korea.
2型糖尿病是一种以血液中高糖水平为特征的多因素疾病。为控制高血糖，如果单药治疗未能实现血糖控制，建议采用联合治疗。二肽基肽酶-4（DPP-4）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂联合使用，在安全性和有效性方面都是很有前景的联合治疗方案。尽管这两种药物联合治疗有其价值，但这两类药物之间的药代动力学药物相互作用仅在少数药物中进行过评估。因此，我们根据代谢和转运体介导的药物相互作用信息以及在韩国上市的DPP-4抑制剂和SGLT2抑制剂之间的人体药物相互作用研究，对潜在的药代动力学药物相互作用进行了综述。
